A new RNA-based drug, Lepodisiran, has stunned researchers by reducing lipoprotein(a) by 94% with a single dose. But are physicians ready to embrace it?
In a Sermo poll of over 600 physicians, 85% said the reduction in Lp(a) could be extremely or moderately significant in preventing cardiovascular disease. However, confidence is tempered by calls for more data: only 20% of physicians are “very confident” in Lepodisiran’s long-term safety, while 40% cited unknown long-term side effects as their top concern, followed closely by limited real-world data and cost issues.
“While the reduction is promising, real-world safety profiles and long-term outcomes are essential before widespread use.” – Pathologist on Sermo
“We’ve seen these types of drugs before. Until we see hard endpoints like reduced mortality, the clinical value remains uncertain.” – Cardiologist on Sermo
Physicians say they’re cautiously open to prescribing it, 62% report being very or somewhat likely to offer it to high-risk patients if approved. But when it comes to increasing confidence, 72% want more long-term cardiovascular outcomes and real-world safety data. Some physicians on Sermo also raised patient hesitancy around RNA-based therapies.
The takeaway
Lepodisiran could mark a breakthrough in cholesterol care, offering physicians a tool in reducing “stealth” cholesterol. But among physicians, excitement is balanced by caution. Safety, affordability, and real-world outcomes will ultimately determine whether this drug fulfills its promise.
Join the conversation on Sermo
Are you considering Lepodisiran for your patients? What data would convince you to prescribe it?
Join Sermo today to explore physician-only discussions around new RNA-based therapies and what’s next in cholesterol care.
